key: cord-0725606-yc0jh3qp
authors: Hoenigl, Martin
title: Invasive Fungal Disease complicating COVID-19: when it rains it pours
date: 2020-09-05
journal: Clin Infect Dis
DOI: 10.1093/cid/ciaa1342
sha: 2bc35005ef9370b718ed1e856db28a6af5f0796b
doc_id: 725606
cord_uid: yc0jh3qp

nan

M a n u s c r i p t 2 A century ago, the 1918 influenza pandemic changed the world, when one-third of the world's population became infected and over 50 million people died. By examining lung tissue samples preserved in paraffin blocks, Morens and colleagues from the National Institute of Allergy and Infectious Diseases found only out 80 years later that in fact the majority of deaths in the 1918 influenza pandemic resulted not from viral pneumonia, but from secondary bacterial pneumonia caused by common upper respiratory-tract bacteria [1] . Now we are facing another devastating worldwide pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with to date over 24 million individuals infected and a mortality rate greater than 3%. While superinfections have been rarely reported in the beginning of the current pandemic, they are now on the rise, particularly reports about secondary fungal disease.

SARS-CoV-2-associated pulmonary aspergillosis (CAPA) has been the predominant fungal disease adding insult to injury in coronavirus disease 2019 (COVID-19) patients with acute respiratory distress syndrome (ARDS), and while the pathogenesis is incompletely understood, there are several immunological mechanisms that may contribute to the development of CAPA and other fungal diseases. SARS-CoV-2 virus invasion results in the release of dangerassociated molecular patterns (DAMPs) which act as endogenous signals that exacerbate the immune and inflammatory response leading to lung injury [2, 3] . Importantly, DAMPs are known to play a central role in the pathogenesis of fungal diseases [4] . Moreover, collateral effects of host recognition pathways required for the activation of antiviral immunity may, paradoxically, contribute to a highly permissive inflammatory environment that favors fungal pathogenesis [2] .

To date over 100 cases of CAPA have been reported from many countries in Europe, Asia, Australia and South America [2, [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] , often occurring in patients with no other risk factor than COVID-19 associated ARDS [2] , and multiple of them proven by autopsy [17, 19, 20] . In A c c e p t e d M a n u s c r i p t 3 contrast, there are fewer reports on other fungal diseases complicating COVID-19, including two cases of Saccharomyces cerevisiae fungaemia caused by fungal translocation [21] after administration of probiotic preparations containing Saccharomyces [22] , cases of invasive Candida infections [23] , and a case of invasive fusariosis [24] . Now, in this issue of Clinical Infectious Diseases, White and colleagues from the United Kingdom report a 26.7% incidence of invasive fungal disease in a multicenter prospective cohort of COVID-19 intensive care patients, including a 12.6% incidence of invasive yeast infections [25] . CAPA still accounted for the majority of fungal disease cases (14% of the cohort), although this was lower than the average incidence rate of 26% reported in previous studies.

Of note, CAPA incidence rates reported to date have varied widely, ranging between 4%[15] -35% [19] in mechanically ventilated critically-ill patients. Factors that may contribute to the differing incidence rates are threefold. First, fungal diseases and specifically CAPA are difficult to diagnose and are likely underestimated, particularly in the setting of COVID-19 associated ARDS, where the clinical picture and radiological findings of CAPA resemble those of severe COVID-19 [7, 26] , blood tests lack sensitivity due to the primarily airway invasive growth of Aspergillus in non-neutropenic patients [27] , and most importantly sampling of the primary site of infection is rarely performed, due to the risk of COVID-19 transmission through bronchoscopies with bronchoalveolar lavage (BAL) or autopsies (due to the overlap of imaging findings between CAPA and COVID-19, postmortem fine needle biopsies alone may not be sufficient to detect focal CAPA [28] ), which are both aerosole creating procedures [29] . Random diagnosis of CAPA, without specifically and creatively searching for it is therefore virtually impossible in this setting, and diagnosis requires specific expertise and awareness, which is rare given that fungi are neglected pathogens [30, 31] . Also, in many places around the world, clinical A c c e p t e d M a n u s c r i p t 4 mycology remains a neglected subspecialty in the medical field, sometimes overlooked even within the specialty of infectious diseases where the focus is often laid on more common bacterial and viral infections. Funding for research on fungal diseases is limited compared to funding available for other infectious diseases that cause similar or lower mortality, a fact that is outlined by the Global Funding of Innovation for Neglected Diseases (G-Finder) Report [31] .

Second, screening of critically-ill COVID-19 patients for CAPA is necessary but serum galactomannan (GM), the screening standard in other high-risk settings, has limited utility because of a low sensitivity of only 21% for CAPA [2] . Screening with serum (1-3)-ß-D-glucan (BDG) might show better performance characteristics and also detect fungal diseases caused by Candida spp., and as such BDG is also recommended as basic screening test in the present study by White and colleagues [25] . However, most hospitals don't have access to rapid in house BDG test results, limiting the feasibility of BDG screening, something that may change in the near future with the introduction of the Fungitell STAT™ rapid test that allows for qualitative detection of BDG from serum, with results available in approximately one hour [32] . Also, BDG is a panfungal marker and not specific for CAPA or any other fungal disease, requiring further evaluations and testing of blood and bronchoalveolar lavage (BAL) with e.g. culture, GM, PCR, or the Aspergillus lateral flow assay in those who screen positive [33] . Given the difficulties to obtain BAL, non-directed bronchial lavage (NBL) and tracheal aspiration (TA) samples would be the logical alternatives for screening for CAPA and other pulmonary mold infections, but non-culture based methods such as GM, PCR or the LFA are not validated for respiratory specimens other than BAL Therefore screening of NBL/TA would have to rely primarily on fungal culture, which would also require further work up given imperfect specificity. Taking into account feasibility and performance, screening of mechanically ventilated COVID-19 patients A c c e p t e d M a n u s c r i p t 5 for fungal disease using serum BDG and/or screening for mold disease using direct microscopy and high volume fungal culture [34, 35] of NBL/TA may be the preferable options with acceptable sensitivities, but positive screening results should always trigger further work up for fungal diseases.

Third, incidence of CAPA may differ depending on treatment modalities for severe COVID-19. Particularly dexamethasone treatment, as well as anti-IL-6 therapy may result in an increasing rate of superinfections, including CAPA in critically-ill COVID-19 patients [36] .

Indeed most patients received anti IL-6-treatment with tocilizumab, as well as corticosteroids in some of the studies with high CAPA incidence [37] . While in other studies high incidence of CAPA was observed despite the absence of systemic corticosteroid use [19] , the use of corticosteroids significantly increased the likelihood of CAPA in the present study by White et al. [25] . Other environmental factors, such as construction activity for temporary facilities and hospitals that may not adhere to rigorous ventilation requirements present within permanent hospitals may also increase fungal exposure beyond what would normally be encountered within hospitals and/or intensive care units [38] .

CAPA associated mortality rates have been devastating with cohort studies reporting consistently mortality rates above 40% [5, 7, 8, 14, 16, 19] . While it was shown recently that CAPA was significantly [14] associated with mortality among intubated patients with COVID-19 [7, 8, 19] , it had remained unknown whether antifungal treatment could improve mortality rates. White et al. now report significantly higher mortality rates in those with fungal disease (53% versus 32%; p=0.04), which was driven specifically by patients with fungal disease who were not receiving antifungal therapy (90% mortality), while mortality was significantly A c c e p t e d M a n u s c r i p t 6 (p=0.008) reduced to 38.5% in those with fungal disease who received antifungal therapy [25] .

These findings outline the utmost importance of early and appropriate antifungal therapy in order to improve CAPA survival. While in general, outside the hematologic malignancy setting voriconazole remains the recommended first-line treatment for invasive aspergillosis [39, 40] , there are several drawbacks to using voriconazole in severe COVID-19 patients. Voriconazole is metabolized via CYP2C19, CYP2C9, and CYP3A4 and among the drugs most frequently associated with major drug-drug interactions in the ICU setting [41] . Voriconazole also shows interactions with with some experimental COVID-19 therapies, including hydroxychloroquine, atazanavir, lopinavir/ritonavir, although there seem to be no clinically relevant interactions with remdesivir and dexamethasone [42] . Enthusiasm for voriconazole is also tampered by its narrow therapeutic window [43] . While more limited data exist for isavuconazole outside the hematologic malignancy setting, isavuconazolewhen compared to voriconazoleshowed a favourable pharmacokinetic profile and was associated with fewer toxicities and also fewer drugdrug interactions and may therefore be treatment of choice [44] . Liposomal Amphotericin B is the primary alternative option for treatment of IPA in the ICU [39] , however the drug is nephrotoxic and may thus result in a further decline of renal function [45] , which is particularly relevant for patients infected by SARS-CoV-2 which has shown renal tropism and is a frequent cause of kidney injury [46] . However, reports of azole resistance in CAPA are emerging [47] [48] [49] , and in those cases liposomal Amphotericin B may be the treatment of choice [50] . New antifungal classes currently under development, namely fosmanogepix (phase 2b study currently enrolling CAPA patients) and olorofim [51] may have efficacy similar to triazoles without the same burden of drug-drug interactions and toxicity, and may therefore overcome the limitations of currently available antifungals and become the preferred treatment options in the near future.

A c c e p t e d M a n u s c r i p t 7 When interpreted in conjunction with previous findings, the high fungal disease incidence and associated mortality rates reported in the study by White et al. may open the door for trials evaluating antifungal prophylaxis in COVID-19 ARDS patients. In one earlier single center study, inhaled liposomal amphotericin B prophylaxis was effectively used to tackle high rates of CAPA in an Belgian ICU [19] . While for prophylaxis trials isavuconazole or posaconazole may be preferable, given the better safety profiles, other new antifungals currently under development, namely rezafungin (a once weekly echinocandin), ibrexafungerp (a triterpenoid, which is a novel class of structurally-distinct glucan synthase inhibitors), and PC945e (an inhaled broad spectrum azole with a favourable safety profile) may be viable options, once approved [51] .

In conclusion, fungal diseases, and particularly CAPA add insult to injury in a significant proportion of critically-ill COVID-19 patients and are associated with high mortality rates, which may be reduced by early diagnosis and initiation of appropriate antifungal therapy. In the absence of antifungal prophylaxis, screening of COVID-19 ARDS patients for CAPA and other fungal diseases is essential.

A c c e p t e d M a n u s c r i p t 8 Acknowledgments

The content is solely the responsibility of the author and does not necessarily represent the official views of the National Institutes of Health.

The work was partially supported by grants from the National Institutes of Health:

UL1TR001442.

A c c e p t e d M a n u s c r i p t 9

Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness

COVID-19 Associated Pulmonary Aspergillosis (CAPA)-From Immunology to Treatment

Danger-associated molecular patterns (DAMPs) in acute lung injury

DAMP signaling in fungal infections and diseases

Prevalence of putative invasive pulmonary aspergillosis in critically ill patients with COVID-19

Invasive fungal diseases during COVID-19: We should be prepared

COVID-19 Associated Pulmonary Aspergillosis

COVID-19 Associated Pulmonary Aspergillosis

COVID-19 associated pulmonary aspergillosis (CAPA): An Australian case report

Ventilator-associated pneumonia involving Aspergillus flavus in a patient

Fatal Coronavirus Disease 2019-associated Pulmonary Aspergillosis; A Report of Two Cases and Review of the Literature

Is the COVID-19 Pandemic a Good Time to Include Aspergillus Molecular Detection to Categorize Aspergillosis in ICU Patients? A Monocentric Experience

Isolation of Aspergillus spp. in respiratory samples of patients with COVID-19 in a Spanish tertiary care hospital

Epidemiology of invasive pulmonary aspergillosis among COVID-19 intubated patients: a prospective study

Incidence of invasive pulmonary aspergillosis among critically ill COVID-19 patients. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases

COVID-19-associated pulmonary aspergillosis (CAPA) in patients admitted with severe COVID-19 pneumonia: An observational study from Pakistan

Confirmed Invasive Pulmonary Aspergillosis and COVID-19: the value of postmortem findings to support antemortem management

Invasive aspergillosis in patients with severe COVID-19 pneumonia. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases

COVID-19-associated invasive pulmonary aspergillosis

Invasive pulmonary aspergillosis complicating SARS-CoV-2 pneumonia: A diagnostic challenge

Fungal Translocation: A driving force behind the Occurrence of non-AIDS Events? Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Bloodstream Infection by Saccharomyces cerevisiae in Two COVID-19 Patients after Receiving Supplementation of Saccharomyces in the ICU

Incidence of co-infections and superinfections in hospitalised patients with COVID-19: a retrospective cohort study. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases

Invasive pulmonary fusariosis in an immunocompetent critically ill patient with severe COVID-19. Clinical microbiology and infection : the official publication of the European Society of

A national strategy to diagnose COVID-19 associated invasive fungal disease in the ICU

Diagnosing COVID-19-associated pulmonary aspergillosis

Point-of-care diagnosis of invasive aspergillosis in non-neutropenic patients: Aspergillus Galactomannan Lateral Flow Assay versus Aspergillus-specific Lateral Flow Device test in bronchoalveolar lavage

Late histopathologic characteristics of critically ill COVID-19 patients: Different phenotypes without evidence of invasive aspergillosis, a case series

American Association for Bronchology and Interventional Pulmonology (AABIP) Statement on the Use of Bronchoscopy and Respiratory Specimen Collection in Patients with Suspected or Confirmed COVID-19 Infection

Fungal diseases as neglected pathogens: A wake-up call to public health officials

Searching for a change: The need for increased support for public health and research on fungal diseases

Performance characteristics of Fungitell STAT™, a rapid (1→3)-β-D-glucan single patient sample in vitro diagnostic assay

Performance of galactomannan, beta-d-glucan, Aspergillus lateral-flow device, conventional culture, and PCR tests with bronchoalveolar lavage fluid for diagnosis of invasive pulmonary aspergillosis

High-volume culture and quantitative realtime PCR for the detection of Aspergillus in sputum. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases

Performance of the Bronchoalveolar Lavage Fluid Aspergillus Galactomannan Lateral Flow Assay with Cube Reader for Diagnosis of Invasive Pulmonary Aspergillosis: a Multicenter Cohort Study

Invasive aspergillosis in glucocorticoid-treated patients

Epidemiology of invasive pulmonary aspergillosis among COVID-19 intubated patients: a prospective study

Invasive Aspergillosis as an Underrecognized Superinfection in COVID-19. Open Forum Infectious Diseases

Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. Clinical infectious diseases : an official publication of the Infectious Diseases Society of

Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clinical microbiology and infection : the official publication of the

Important drug classes associated with potential drug-drug interactions in critically ill patients: highlights for cardiothoracic intensivists

on behalf of the Society of Infectious Diseases P. Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options

Potential factors for inadequate voriconazole plasma concentrations in intensive care unit patients and patients with hematological malignancies

therapy. Drug design

Optimal management of acute kidney injury in critically ill patients with invasive fungal infections being treated with liposomal amphotericin B

Multiorgan and Renal Tropism of SARS-CoV-2

Recovery of a triazole-resistant Aspergillus fumigatus in respiratory specimen of COVID-19 patient in ICU -A case report

Multi-triazole-resistant Aspergillus fumigatus and SARS-CoV-2 co-infection: A lethal combination

Azole-Resistant COVID-19-Associated Pulmonary Aspergillosis in an Immunocompetent Host: A Case Report

The diagnosis and treatment of invasive aspergillosis in Dutch haematology units facing a rapidly increasing prevalence of azole-resistance. A nationwide survey and rationale for the DB-MSG 002 study protocol

New drugs target growing threat of fatal fungi

A c c e p t e d M a n u s c r i p t 11